Compare RBC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBC | GH |
|---|---|---|
| Founded | 1919 | 2011 |
| Country | United States | United States |
| Employees | 5334 | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 17.3B |
| IPO Year | N/A | 2018 |
| Metric | RBC | GH |
|---|---|---|
| Price | $600.05 | $162.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $510.00 | $119.79 |
| AVG Volume (30 Days) | 255.3K | ★ 2.6M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $15.20 | $33.30 |
| Revenue Next Year | $12.36 | $28.27 |
| P/E Ratio | $64.90 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $364.50 | $40.36 |
| 52 Week High | $667.69 | $174.08 |
| Indicator | RBC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 72.59 |
| Support Level | $558.81 | $94.02 |
| Resistance Level | $607.45 | N/A |
| Average True Range (ATR) | 17.90 | 7.15 |
| MACD | -4.66 | 2.39 |
| Stochastic Oscillator | 10.51 | 80.31 |
RBC Bearings is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: industrial, which generates the most revenue, and aerospace and defense. The A&D segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.